- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
- Paralegals
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
September 22, 2023Robins Kaplan Attorneys Named 2023 New York Super Lawyers and Rising Stars
-
September 12, 2023Annie Huang Receives Asian Leadership Award from Profiles in Diversity Journal
-
September 12, 2023Robins Kaplan Partners Named to 2024 Lawdragon 500 Leading Litigators in America Guide
-
September 26-28, 20236th Annual LF Dealmakers Forum
-
September 28-29, 20232023 Midwest IP Institute
-
October 4, 2023Lying, Cheating, and Stealing Seminar 2023
-
August 21, 2023Colorado Expands Antitrust Protection
-
July 18, 2023Copyright: Rights Even Heroes Can't Protect
-
August 2023Minnesota Bans Non-Competes Formed on or After July 1, 2023: Assessing Remaining Strategies to Protect Confidential Information and Trade Secrets
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Patentability, Biosimilars Top Life Sciences Issues for 2012
For the life sciences industry, 2012 will be a year when a lot of things are likely to come together.
January 13, 2012
For the life sciences industry, 2012 will be a year when a lot of things are likely to come together, industry attorneys and executives told Bloomberg BNA during telephone interviews and e-mail exchanges in December.
They indicated that it could be a year when clarity about what is patentable subject matter is achieved from at least one and perhaps two Supreme Court rulings and when personalized medicine, which cuts across federal agencies, the private sector, and a number of other life sciences issues, could definitely become the focus of the industry. And it could be a year when implementing the abbreviated biosimilars approval pathway will result in stronger collaborations among biotechnology, pharmaceutical, and generic drug companies.
Reproduced with permission from Life Sciences Law & Industry Report, 6 LSLR 47 (Jan. 13, 2012). Copyright 2012 by The Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.com
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.